Doctor of Philosophy (PHD)
Biochemistry and Molecular Biology (Medicine)
Date of Defense
First Committee Member
Joaquin J. Jimenez
Second Committee Member
Thomas K. Harris
Third Committee Member
Fourth Committee Member
This proof of principle study explores dendrimer based technology in designing and implementing tissue-specific targeting dendrimers that can act as carriers of biologically active proteins in the treatment of disease. Here, we show a dendrimer based delivery system is effective in delivering a functionally active protein to a tissue-specific target, in this case skeletal muscle, and show in vivo therapeutic effects in the treatment of Type II Diabetes. Out of the many proteins involved in glycolysis within skeletal muscle cells whose mis-regulation can be observed in the diabetic disease state, we have selected one, PROTEIN A, for use in this proof-of-principle study. Here we describe the effectiveness of our dendrimer based system comprised of a Poly(amido amine) (PAMAM) generation 5 (G5) dendrimer and skeletal muscle targeting peptides (SMPTs), denoted as G5-SMTP, in delivering PROTEIN A to skeletal muscle. The cumulative data presented here demonstrates that G5-SMTP can successfully be used as a platform for skeletal muscle targeted delivery of the functionally active protein, PROTEIN A, to produce therapeutic effects in diabetic murine models.
Dendrimer; Diabetes; Skeletal Muscle Targeting Peptide
Hughes, Keryn Effie, "Targeted Drug Delivery: Dendrimer Technology for the Delivery of Biologically Active Therapeutics" (2015). Open Access Dissertations. 1500.